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Abstract
Background: The study of pulmonary biomarkers with noninvasive methods, such as the analysis of exhaled
breath condensate (EBC), provides a useful approach to the pathophysiology of asthma. Although many recent
publications have applied such methods, numerous methodological pitfalls remain. The first stage of our study
consisted of validating methods for the collection, storage and analysis of EBC; we next sought to clarify the utility
of analysing nitrogen oxides (NOx) in the EBC of asthmatics, as a complement to measuring exhaled nitric oxide
(FeNO).
Methods: This hospital-based cross-sectional study included 23 controls matched with 23 asthmatics. EBC and
FeNO were performed and respiratory function measured. Intra-assay and intra-subject reproducibility were
assessed for the analysis of NOx in the EBC of 10 healthy subjects.
Results: The intraclass correlation coefficient (ICC) was excellent for intra-assay reproducibility and was moderate
for intra-subject reproducibility (Fermanian’s classification). NOx was significantly higher in asthmatics (geometric
mean [IQR] 14.4 μM [10.4 - 19.7] vs controls 9.9 μM [7.5 - 15.0]), as was FeNO (29.9 ppb [17.9 - 52.4] vs controls 9.6
ppb [8.4 - 14.2]). FeNO also increased significantly with asthma severity.
Conclusions: We validated the procedures for NOx analysis in EBC and confirmed the need for assays of other
biomarkers to further our knowledge of the pathophysiologic processes of asthma and improve its treatment and
control.
Background
Inflammatory and oxidative changes in lungs are early
indicators of the pathophysiology of many respiratory
diseases [1-4]. Over the past decade, investigations of
exhaled breath have multiplied, through the study of
various compounds, both volatile, such as NO (FeNO),
and non-volatile, especially nitrogen oxides (NOx).
Understanding asthma requires markers of disease
severity and control that can help to predict the risk fac-
tors for exacerbation [5,6]. Clinical and spirometric data
are used in standardised questionnaires for follow-up
and control. A more precise approach to the pathophy-
siology of asthma through the study of pulmonary bio-
markers is interesting for early or even subclinical
asthma diagnoses [4].
The study of FeNO is well standardised today; this
compound is thought to reflect inflammatory conditions
in the tissue (airway wall or alveolar compartments)
[7-10]. Nonetheless, this biomarker does not provide
any specific help in understanding the pathophysiologi-
cal processes in asthma [11,12]: that is, it does not pro-
vide information on the phenomena of oxidative stress
that play an important role in its pathogenesis. More-
over, FeNO is difficult to measure in young children [2].
On the other hand, the study of nonvolatile compounds
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mising in this regard. This noninvasive method is both
simple and reproducible, making it possible to explore
the more specific factors of both inflammation and oxi-
dative stress, through the study of NOx in EBC [13-15].
Despite the wide interest in this method, many metho-
dological pitfalls remain, including the choice of systems
for collection, storage and analysis [3,11]. The high intra
assay variability of biomarker measurements is an
important factor that explains its limited use in daily
clinical practice [10,16]. The necessity for standardisa-
tion has been the subject of numerous publications over
the past five years [11].
The first stage of our study consisted of validating the
methods for the collection, storage, and analysis of EBC;
we then used these rigorous methods to clarify the uti-
lity of analysis of NOx in the EBC of subjects with
asthma, as a complement to FeNO measurements. We
compared these two biomarkers in a population of
patients with asthma and of controls matched for age
and smoking habits.
Methods
Study population
This cross-sectional single-center study included 46
volunteer subjects over 18 years of age: 23 healthy non-
atopic controls and 23 subjects with asthma, matched
for age and smoking habits. Subjects were matched for
age in 5-year age groups and for smoking habits by
status.
The inclusion criterion for controls was normal lung
function. Subjects were excluded if they were: pregnant,
had smoked or drunk coffee within the past 4 hours,
had respiratory disorders, had had recent infections (< 3
months) or potential environmental or occupational risk
factors. The inclusion criterion for all subjects with
asthma was the presence of moderate (GINA3) or severe
(GINA4) persistent asthma [5]. Patients treated by
inhaled corticosteroids and bronchodilators were
accepted. The exclusion criteria were the same as for
controls. The Institutional Review Board of Lille Univer-
sity Hospital approved this study.
Questionnaire
The clinical evaluation was based on a standardised
BMRC questionnaire [17].
Lung function
The lung function tests were conducted according to
the 2005 guidelines of the European Respiratory Society
[18,19] and included both slow and forced spirometry,
as well as single-breath CO transfer (TLCO). Slow vital
capacity (SVC), maximum forced expiratory volume in a
second (FEV1), total lung capacity (TLC), FEV1/SVC
ratio and single-breath CO transfer (DLCO) were
examined.
FeNO measurement
FeNO levels were measured with a chemiluminescence
NO analyzer (NOx 8000, SERES Aix en Provence,
France). The examinations were conducted according to
the ATS guidelines [20]]. Subjects were seated and
noseclips were not used. After deep inspiration of air
without NO (NO-free), NO concentrations were mea-
sured during controlled expiration, at the first stable
FeNO plateau for at least three seconds (FeNO varia-
tions < 10% or 1 ppb). FeNO was measured twice for
each of the four expiratory flows: 25, 50, 100, and 150
mL/s. We used for our study the mean FeNO of two
measurements at 50 mL/s (FeNO50) and alveolar and
bronchial NO production (respectively CalvNO and
J’awNO) determined from Tsoukias’s model [21] if the
R
2 of the model was greater than 0.64 [22]. We studied
the reproducibility of exhaled NO for 31 controls. The
intraclass correlation coefficients for the four flows
exceeded 0.98 [23].
Collection of EBC
EBC were collected by an Ecoscreen device (Jaeger™,
Würzburg, Germany), previously described [24]. An
electronic spirometer (Ecovent Viasys, Hechberg, Ger-
many) attached to the expiratory circuit allowed us to
monitor the subject’s ventilation. Collection was com-
pleted when the total expired volume reached 200 liters.
Analysis of EBC
The total nitrites (NOx) were assayed by the Griess
method (Griess Reagent Kit, Invitrogen, Cergy Pontoise,
France) with spectrophotometric detection after reduc-
tion of nitrates. The concentration measured represents
the sum of the nitrites and nitrates initially present in
the EBC. We used an enzymatic technique in tubes,
with nitrate reductase (Sigma, St. Quentin Fallavier,
France) for the reduction stage. The limit of detection
(LOD) was 2 μM. The detection rate in our population
was 100% for the subjects with asthma and the controls.
After collection, the condensates were immediately
divided into aliquots and stored at -80°C [25].
In a preliminary study to examine long-term storage
of the biomarkers in the condensates, we assayed the
NOx present in the aliquots from a single sample,
stored at -80°C and thawed at 1 day, 7 days, 1 month
and 2 months after sampling. The short-term stability
after thawing and storage of the aliquots at 4°C was also
assessed.
The reproducibility of the assays for biomarkers in the
EBC was tested in duplicate for 10 healthy controls two
days in a row, so that we could study the reproducibility
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two consecutive days.
Statistical analysis
The statistical analyses were performed with SAS soft-
ware (Cary NC). The intra-assay and intra-subject
reproducibility were assessed by the coefficient of varia-
tion (CV) and the intraclass correlation coefficient
(ICC). Excellent agreement for the ICC was defined as
ranging from 1.00 to 0.91, good from 0.90 to 0.71, mod-
erate from 0.70 to 0.51, slight from 0.50 to 0.31, and
poor from 0.30 to 0.00 (Fermanian 1984). We also used
the method recommended by Bland and Altman [26] to
determine the bias and coefficient of repeatability
between two measurements. Results were presented as
geometric means with their interquartile ranges [IQR].
Descriptive statistics, with tests of normality (Shapiro-
Wilk test) for the FeNO and NOx values in EBC,
showed lognormal distributions. Statistical tests were
performed after logarithmic transformation of the data.
When the values were below the LOD, they were
assigned a value of 0.5 LOD. The association between
FeNO and NOx in EBC was determined with the Spear-
man correlation. Analysis of variance (ANOVA) was
used to compare patients and controls. Analyses of
more than two groups used Tukey’s multiple compari-
son procedure.
Results
Stability and reproducibility
We found good long-term stability (93%) for the NOx
measurements. This demonstrates very low loss during
storage relative to the values obtained immediately after
sampling. The NOx assays performed on three consecu-
tive days (short-term stability) remained consistently
stable (98%). These results are similar to these achieved
by other teams [26,27].
The intra-assay and intra-subject reproducibility of the
NOx assay in the EBC of 10 controls were assessed.
Table 1 summarises the results of this analysis. The ICC
for intra-assay reproducibility was excellent, according
to Fermanian’s classification. The ICC for intra-indivi-
dual reproducibility over two consecutive days was mod-
erate. Bland and Altman’sm e t h o da p p l i e dt ot h e
difference in the data obtained in these two studies of
reproducibility shows that all the assays are within the
limits of agreement.
Subjects with asthma vs controls
Table 2 presents the general characteristics of the sub-
jects with asthma and the matched controls. The results
of the lung function tests show lower values in patients.
The conditions of EBC collection were similar for the
subjects with asthma and the controls, for both the
duration and volume of collection.
Table 3 summarises the biomarker levels in exhaled
air. There was a statistically significant increase in the
FeNO50 concentrations (p < 0.001), CalvNO (p = 0.002),
J’awNO (p = 0.001) and NOx (p = 0.046) in the EBC of
subjects with asthma compared with the controls. When
we took into account the severity of asthma, this
increase persisted for FeNO50 (p < 0.001), alveolar NO
(p = 0.003) and bronchial NO (p = 0.005) (Table 4).
Table 1 Intra-assay and intra-individual reproducibility of
NOx analysis in EBC
ICC
1 CV
2 Coef of Repeatability
3 Bias
3
Intra-assay 0.98 4.9% (4.7) 0.28 1.0 μM
Intra-individual 0.58 21.8% (14.3) 1.9 1.8 μM
1 Intraclass correlation coefficient
2 Coefficient of variation: mean (SD)
3 Bland and Altman test
Table 2 Patient’s characteristics
Asthma (n =
23)
Controls (n =
23)
Statistics
1
Age (years)
a 50.0 [30.0 - 56.0] 46 [28.0 - 51.0] 0.534
Height (meter)
a 1.65 [1.62 - 1.75] 1.68 [1.62 - 1.75] 0.767
Weight (kg)
a 73.0 [63.0 - 84.0] 70.0 [61.0 - 75.0] 0.347
BMI (kg/m2)
a 26.5 [22.5 - 27.7] 23.4 [21.7 - 26.1] 0.173
Male
b 12 (52.2) 7 (30.4) 0.134
Smoking
b 1.0
Ex-smoker 4 (17.4) 4 (17.4)
Smoker 6 (26.1) 6 (26.1)
Non-smoker 13 (56.5) 13 (56.5)
TLC (obs/pred)
a,c 106.4 [100.6 -
116.0]
108.6 [100.2 -
112.6]
0.859
SVC (obs/pred)
a,c 90.5 [81.0 - 95.4] 106.6 [100.4 -
119.2]
< 0.001
FEV1 (obs/pred)
a,c 56.5 [50.3 - 73.7] 107.1 [100.8 -
115.6]
< 0.001
FEV1/SVC (obs/pred)
a,c 69.4 [57.2 - 77.9] 102.8 [96.7 -
105.9]
< 0.001
MMEF (obs/pred)
a,c 23.4 [14.5 - 38.5] 95.7 [79.2 -
107.6]
< 0.001
TLCO (obs/pred)
a,c 78.5 [68.5 - 94.0] 90.0 [81.0 -
103.5]
0.102
Total expired volume
(L)
a
204 [200 - 250] 205 [200 - 225] 0.629
2
Total volume of EBC
(mL)
a
4.00 [3.50 - 5.00] 4.00 [3.75 - 4.50] 0.787
2
Time (min)
a 20 [16 - 25] 20 [18 - 24] 0.911
2
BMI: body mass index, TLC: total lung capacity, SVC: slow vital capacity, FEV1:
forced expiratory volume in 1s, MMEF: Maximum mid-expiratory flow, TLCO:
carbon monoxide gas transfer
a data expressed as median [IQR]
b data expressed as n (%)
c data expressed as % of predicted values
1 p(Chi-2)
2 ANOVA on the ranks
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EBC and exhaled NO but found no significant
relationships.
Discussion
This study validated the methodology of analysis of
NOx in EBC and demonstrated satisfactory intra-assay
and intra-individual reproducibility and consistent stabi-
lity. The comparison of FeNO and NOx in EBC showed
substantially higher concentrations in asthma patients.
Moreover, the exhaled NO concentration increased
when we took the severity of the asthma into account.
The study of exhaled NO is currently the most com-
monly used technique for which standardisation has
been demonstrated to be compatible with clinical use
[3]. Interest in EBC continues to increase because its
safety and noninvasiveness make it a method of choice
for studying the pathophysiologic mechanisms of lung
diseases. Nonetheless, its development as a research tool
remains slow because of a lack of standardisation and
reference values for the biomarkers studied [3,27]. The
standardisation that we sought to develop for the collec-
tion of condensates and the assay of biomarkers was
thus an essential stage in advancing the use of EBC ana-
lysis for clinical and research purposes.
Our results showed an excellent level of standardisa-
tion for collection (Table 2) with a volume of 4 mL of
EBC for a total expiratory volume set at 200 L. The
decision to standardise according to expired volume
rather than time thus appeared to be correct, as our
results showed that the volumes of condensates
exhibited low variability, both within and between con-
trol and patient groups.
The detection rate of NOx in the crude EBC was
excellent. In a preceding study [24] we showed the
importance of the choice of coating agent used for the
various components of the EBC collection apparatus, as
others have suggested [28-30], for optimising biomarker
detection. Accordingly, the assays were performed on
crude condensates thus avoiding sample handling and
loss of biomarkers during lyophilisation and resolubilisa-
tion. These efforts provided very satisfactory detection,
greater than 95%, for the NOx.
We also studied intra-assay and intra-individual repro-
ducibility. The comparison of our results with those of
other studies nonetheless remained difficult because
these studies used different modes of sample collection
and different assay techniques with different levels of
reproducibility [11]. That is, most studies have examined
intra-assay reproducibility [13,31,32]; reproducibility
from day to day has been studied much more rarely,
and intra-individual reproducibility on two consecutive
days still less often [31,33]. Only a few other studies
have, like ours, simultaneously examined the intra-assay
and intra-subject reproducibility of the biomarkers. Our
results for NOx in EBC (coefficients of variation (CVs)
= 4.7%) were similar to those of other studies [13,31]
who found mean CVs of 3.11% and 4.9% respectively,
but better than those from an older study [32] which
reported an ICC of 0.71 in the nitrite assay (ICC in this
study = 0.98 for NOx).
The intra-subject reproducibility for NOx appeared
similar to that found by Chladkova et al. [33] but was
better than that reported by Chow et al. [31].
Relatively few previous studies have explored the con-
servation of markers in the condensates. Our results,
better than those found by either Chladkova et al. [33]
or Vogelberg et al. [34], showed that NOx stability was
good in both the short and long term storage scenarios
studied here.
It is not easy to compare our NOx levels with those in
the literature because each team has assayed different
forms of NOx (nitrites, nitrites/nitrates, total nitrites) by
Table 3 Result of biomarkers in exhaled air
Asthma (n = 23) Controls (n = 23) Statistics
b
FeNO50 (ppb)
a 29.9 [17.9 - 52.4] 9.6 [8.4 - 14.2] < 0.001
CalvNO (ppb)
a 3.7 [2.7 - 6.3] 1.7 [1.1 - 2.8] 0.002
J’awNO (nL/min)
a 80.6 [56.7 - 116.9] 30.9 [25.7 - 46.3] 0.001
NOx (μM)
a 14.4 [10.4 - 19.7] 9.9 [7.5 - 15.0] 0.046
FeNO50: Fractional exhaled nitric oxide at 50 mL/s, CalvNO: Alveolar NO
concentration, J’awNO: Bronchial NO concentration, NOx: Nitrogen oxides
a data expressed as geometric mean [IQR]
b ANOVA
Table 4 Result of biomarkers in exhaled air, taking asthma severity into account
GINA4 (n = 12) GINA3 (n = 11) Controls (n = 23) Statistics
1
FeNO50
a 32.6 [16.8 - 70.9] 27.6 [18.1 - 42.3] 9.6 [8.4 - 14.2] < 0.001
§,£
CalvNO (ppb)
a 2.8 [2.0 - 2.8] 4.4 [2.9 - 6.6] 1.7 [1.1 - 2.8] 0.003
§
J’awNO (nL/min)
a 79.0 [44.3 - 175.4] 81.6 [58.5 - 114.4] 30.9 [25.7 - 46.3] 0.005
§,£
NOx (μM)
a 12.5 [9.0 - 19.5] 16.9 [14.0 - 19.7] 9.9 [7.5 - 15.0] 0.074
FeNO50: Fractional exhaled nitric oxide at 50mL/s, CalvNO: Alveolar NO concentration, J’awNO: Bronchial NO concentration, NOx: Oxides of nitrogen
a data expressed as geometric mean [IQR]
1 ANOVA
§ Significant increase GINA 3 vs controls
£ Significant increase GINA 4 vs controls
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fluorescence or ionex HPLC) [11]. Comparison with
other studies is much easier for FeNO, which has the
best standardisation [7-10]. Our mean levels in controls
(9.6 ppb) were similar to those reported by other teams
[13,35].
The FeNO study made it possible to discriminate
between subjects with asthma and controls, but also
between subjects with asthma of different degrees of
severity and controls. Nonetheless, the hypothesis was
that NOx accurately reflects oxidation in the EBC while
FeNO is an indirect indicator of inflammation. That is,
it is the product of arginine transformation by NO
synthase and appears to be involved in the regulation of
inflammation in pulmonary diseases. This unstable pro-
duct reacts in aqueous solution with oxygen or the radi-
cal species formed by oxidative stress, such as the
superoxide anion, to form, among other molecules, the
relatively stable nitrogen oxides (NOx), including nitrites
(NO2
-) and nitrates (NO3
-) [14,15]. This production
increases in situations of oxidative stress. This is the
reason behind our choosing to study this biomarker of
oxidative stress, an important phenomenon to consider
with asthma, and one that simultaneously but indirectly
reflects inflammation. NOx production can vary accord-
ing to the specific lung disease [13,14], the treatment
administered [36] and smoking habits [37]. The impact
of age on FeNO has been studied [38] but its impact on
NOx production has been less studied [39]. Hence, we
took care to match subjects with asthma and their con-
trols for age and smoking status.
The concentrations of FeNO and of NOx in the EBC
both differed significantly between subjects with asthma
and controls. On the other hand, we did not find a sig-
nificant difference according to the severity of asthma,
although a trend was nevertheless evident (Table 4).
Other authors have found significant differences in
FeNO levels in patients with mild compared with severe
asthma, but observed findings similar to ours for mod-
erate and severe asthma, the categories compared in
our study design [14,40]. The absence of a correlation
in our study between NOx in the EBC and exhaled,
alveolar, and bronchial NO may be explained by the use
of different NO transformation pathways. The formation
of peroxynitrite, which interacts with some amino acids,
has harmful consequences on the properties of some
proteins, which may explain the aggravation and even
the lack of response to some treatment. Accordingly,
assays of NOx alone in our study did not appear suffi-
cient, and the exploration of this other pathway of NO
transformation by the peroxynitrite assay might be use-
ful in explaining the pathophysiology of asthma
aggravation.
Conclusions
The results of our study confirmed the pertinence of the
study of FeNO in subjects with asthma. The NOx assay
in EBC remained insufficient to provide supplementary
information but may be interesting in populations
where FeNO cannot be studied, as in young children
[2]. The study of exhaled breath condensates therefore
remained seductive as a clinical and research tool but
the continuation of assays of other biomarkers remains
essential to further our knowledge of the pathophysiolo-
gic processes of asthma and improve its treatment and
control. We are working in this direction, continuing to
assay NOx together with peroxynitrite and hydrogen
peroxide (H2O2), in order to further our knowledge of
other oxidation pathways and their role in the occur-
rence of asthma.
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